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Abstract
Background: Cyclosprin A (CsA) has been widely used clinically to treat the patients who have undergone organ
transplantation or acquired autoimmune disease. The purpose of this study is to determine the effects of three
different doses of CsA (1.5, 7.5, 15 mg/kg body weight) on the skeletal biomechanical proprieties at different
anatomic sites in rats.
Methods: Fifty-six male 3-month-old Wistar rats were divided into five groups. Eight rats were randomly chosen as
the basal group, while the others were randomly distributed into four groups of 12 animals each. One group was
used as controls and received daily subcutaneous injection of 1 ml of saline solution; another three experimental
groups were injected subcutaneously with CsA in a daily dose of 1.5, 7.5, and 15 mg/kg body weight respectively
for 60 days. The bone biomechanical proprieties, the bone mineral density, as well as the trabecular bone
architecture were measured at different anatomic sites, i.e. the lumbar vertebra, the middle femur shaft, and the
proximal femur.
Results: CsA therapy at 7.5 and 1.5 mg/kg can significantly reduce the ultimate force, the ultimate stress and the
energy absorption per unit of bone volume of the lumbar vertebra, with no effect on the middle femur. CsA
therapy at 7.5 mg/kg can significantly reduce the ultimate force, the ultimate stress and the Young’s modulus of
the femoral neck, but not CsA at 1.5 mg/kg. Furthermore, CsA therapy at 7.5 and 1.5 mg/kg can significantly
reduce the bone mineral density of the lumber vertebra and the proximal femur, but have no effect on the middle
femur. CsA therapy at 7.5 and 1.5 mg/kg can also significantly reduce the bone volume fraction of the proximal
tibia and the lumber vertebra, but has no effect on the cortical thickness of the middle femoral shaft. In the 15
mg/kg CsA group only one rat survived, and the kidney and liver histology of the survived rat showed extensive
tissue necrosis.
Conclusion: Long-term use of CsA can weaken the biomechanical properties and thus increase the fracture rate of
the lumbar vertebra and the proximal femur. However, CsA therapy has less effect on the middle femur shaft. The
effects of CsA on skeleton are site-specific.
Background
Cyclosporin A (CsA) has been widely used clinically to
prevent organ rejection in post-transplantation and to
ameliorate the autoimmune disorders. However, since the
patients usually receive a combination of several drugs, the
isolated clinical effects of CsA on human skeleton are still
unclear. Although it is increasingly believed that CsA can
cause bone loss in humans [1,2], it is interestingly found
that CsA monotherapy in renal transplantation patients
can significantly increase lumbar bone mineral density
[3,4]. Yet up to now, a correlation between the daily or
accumulative dose of CsA and fracture frequency has not
been established [5]. It remains to be found out whether
long-term use of CsA will increase the fracture risk in
humans.
There are numerous experimental studies evaluating
the effects of CsA on the bone metabolism. Some in-vivo
studies have demonstrated that CsA in the rats can
induce high-turnover bone loss, resulting in an uncou-
pling of the dynamic bone remodeling cycle with resorp-
tion exceeding formation and leading to an ultimate loss
of trabecular bone [6-8]. Bone histomorphometry in
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increased parameters of bone formation, and decreased
percent trabecular bone volume [6-8]. However, CsA dos
not affect the absolute rate of cortical bone resorption at
the organ level [9]. The effect of CsA on bone mineral
metabolism is dependent on both the dose and the dura-
tion of administration [10,11]. Transforming growth
factor-beta, alendronate, and raloxifene analog may have
potential in modulating the deleterious bone effects of
CsA [7,12,13]. The precise mechanisms involved in CsA-
induced bone loss are still not well defined. Wada et al
suggested that the bone resorption in CsA-treated rats
may be activated by plasma parathyroid hormone (PTH)
[6]. However, Epstein et al founded that PTH may not be
essential for CsA-induced bone loss, and Buchinsky et al
suggested that T lymphocytes appeared to be a prerequi-
site for the development of CsA-induced bone loss
[14,15].
Few studies have evaluated the effects of CsA on bone
mechanical properties. As Jarvinen et al emphasized, we
should not forget that the primary function of the skeleton
is locomotion of the body and that only adequately rigid
and strong bones make this vital function feasible [16]. It
is thus important to evaluate the effects of CsA on bone
mechanical properties. Warren et al. treated the rats with
CsA for 14 consecutive days at a dose of 7 mg/kg body
weight/day, and did not find alteration in biomechanical
properties with respect to the failure torque and the stiff-
ness of the femur diaphysis [17]. However, they reminded
us that testing in torsion emphasizes cortical bone charac-
teristics, and the short-term nature of treatment with this
drug may have failed to significantly influence cortical
bone [17]. It is still necessary to illuminate the detrimental
effect of CsA on bone mechanical proprieties in rats.
In the present study, we hypothesized that the long-
t e r mu s eo fC s Ai nt h er a t sw i l ld a m a g et h eb o n e
mechanical properties, and the detrimental effect of CsA
on biomechanical properties is different in varied skele-
tal anatomy sites.
Methods
Animals
Fifty-six male 3-month-old Wistar rats (200~250 g) pur-
chased from the Model Animal Research Center of Nanj-
ing University were housed with free access to water and
chow with constant 12-hour light-dark cycle environ-
mental conditions. They were all acclimatized for 1 week
before the experiment began. All animal experiments
were approved by the Animal Study Committee of Nanj-
ing University.
Eight rats were randomly chosen as the basal group and
were sacrificed at the beginning of the injection protocol
for the treated rats, while the others were randomly dis-
tributed into four groups of 12 animals each. One group
w a su s e da sc o n t r o l sa n dr e c e i v e dd a i l ys u b c u t a n e o u s
injection of 1 ml of saline solution. Another three experi-
mental groups were injected subcutaneously with CsA
(Novartis Pharmaceuticals, Basel, Switzerland) in a daily
dose of 1.5 mg/kg body weight, 7.5 mg/kg body weight,
and 15 mg/kg body weight respectively [8,11,18]. The
experimental period of the study extended over 60 days.
Biochemical assay of blood and body weight
measurement
After sixty days of the CsA therapy, the rats were exsan-
guinated from the abdominal aorta under anesthesia to
obtain serum for the determination of serum alanine
aminotransferase (ALT), serum aspartate aminotransfer-
ase (AST), serum urea nitrogen (BUN), and serum crea-
tinine (Cr). The body weight was also measured [19].
Evaluation of kidney and liver histologic changes
For histological analysis of the rat’s kidney and liver in
15 mg/kg CsA group, paraffin-embedded 6- μm-thick
sections were stained with hematoxylin and eosin [19].
Bone mineral density and bone length measurement
As we reported in our previous study [19], the L1-5 verte-
bra and the total femur were removed off the soft tissue,
and the bone mineral density (BMD) of the L1-5 vertebra,
the femur mid-diaphseal region (the middle two of the
four equal regions of the femur length, Figure 1) and the
proximal femur region (the proximal one of four equal
regions of the femur length, Figure 1) were measured
using dual-energy X-ray absorptiometry (Hologic
QDR4000, USA). The lengths of humerus, tibia and
femur were measured using vernier caliper.
Mechanical testing
The mechanical test was described in detail in our pre-
vious study [19]: the extrinsic parameters (the ultimate
f o r c e ,t h es t i f f n e s sa n dt h ee n e r g ya b s o r p t i o n )w e r e
obtained directly from the load-deformation curves that
were recorded continually in a computerized monitor
and the intrinsic parameters (the ultimate stress, the
Young’s modulus and the energy absorption per unit of
bone volume) can be computed from extrinsic para-
meters and geometric data. Briefly, a compression force
was applied to the cylinder samples of the L2 body speci-
men at a rate of 2.5 mm/minute (Instron 3367); the L2
body cross sections were assumed to be elliptically
shaped, two diameters, anterior-posterior (a) and left-
right (b), of this cylinder were measured using vernier
caliper and used to calculate the cross-sectional area (S)
(S = πab/4). A bending force was applied to the middle
femur shaft at a speed of 5 mm/minute until fracture
occurred; the femur cross sections were assumed to be
elliptically shaped, the moment of inertia is I = π[ab
3-\(a-
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3]/64: Where a is the width of the cross section
in the medial-lateral direction, b is the width in the ante-
rior-posterior direction, and t is the average cortical
thickness. A cantilever bending force was applied perpen-
dicularly to the femur neck at a speed of 5 mm/minute
until fracture occurred; the femur neck cross sections
were assumed to be elliptically shaped, the section modu-
l u si sW z=πa
2b/32: Where a is the width of the cross
section in the superior-inferior direction, and b is the
width in the anterior-posterior direction.
Bone histomorphometry analyses
The L4 vertebra body and the right proximal tibia meta-
physis were removed off the soft tissue and fixed in 10%
phosphate-buffered formalin for 24 h. The vertebrae and
the tibia metaphyses were then dehydrated in ethanol,
defatted in xylene, and embedded in methyl methacrylate.
The frontal sections were cut at 4 μmt h i c k n e s sw i t ha
microtome (Leica RM2155; Germany) and were stained
with Goldner’s trichrome for quantification of trabecular
bone architecture. A semi-automatic image analysis system
(Image-Pro Plus) was used to measure the bone volume
fraction(%), the trabecular number (#/mm), the trabecular
thickness (μm), and the trabecular separation (μm) [20].
The anterior-posterior cortical thickness of the middle
femoral shaft was measured using vernier caliper [19].
Statistical analysis
All statistical analyses were carried out using SPSS v.13.
The groups were compared by means of 1-way ANOVA
(S-N-K) if the variances were homogeneous; but if not,
Kruskal-Wallis test was used. The statistical differences
were detected among the control group, 1.5 mg/kg CsA
group and 7.5 mg/kg CsA group. All values were
expressed as ¯ X± SD. Statistical significance was accepted
at P < 0.05.
Results
Effects of varying doses of CsA on kidney and liver
function
In the 15 mg/kg CsA group only one rat survived. The
kidney and liver histology of the survived rat showed
extensive tissue necrosis (Figure 2), and the serum ALT,
AST, BUN and Cr levels were respectively 2.5, 2.8, 3, and
1.5 times of the averaged levels of the control group. In
the 7.5 mg/kg CsA group, three rats died. One rat in the
1.5 mg/kg CsA group was excluded in our study due to a
huge neck mass. No significant change in ALT, AST, BUN
and Cr levels was observed among the control group, the
1.5 mg/kg CsA group and the 7.5 mg/kg CsA group
(Table 1).
The kidney and liver histology of the survived rat in 15
mg/kg CsA group
Only one rat survived in the 15 mg/kg CsA group. The
kidney and liver histology of the survived rat showed tis-
sue necrosis (Figure 2).
Effects of varying doses of CsA on the bone length and
the body weight
No significant change in the bone length or the body
weight was observed among the control group, the 1.5
mg/kg CsA group and the 7.5 mg/kg CsA group
(Figure 3).
Effects of varying doses of CsA on bone mineral density
Compared with the control group, both the 1.5 mg/kg
CsA group and 7.5 mg/kg CsA groups had statistically
significant decreases in the BMD and BMC values of the
lumber vertebra and the proximal femur, but had no
significant changes in the BMD and BMC values of the
middle femur. No significant differences in the values of
the Area were obtained among the control group, 1.5
mg/kg CsA group and 7.5 mg/kg CsA group (Table 2).
Effects of varying doses of CsA on bone mechanical
properties
The second lumbar vertebra displayed statistically signif-
icant lower values of the ultimate force, the ultimate
stress and the energy absorption per unit of bone
 
Figure 1 The region defined on the femur.R e g i o nA :t h e
proximal femur region, the proximal one of four equal regions of
the femur length; Region B: the femur mid-diaphseal region, the
middle two of the four equal regions of the femur length.
Chen et al. BMC Musculoskeletal Disorders 2011, 12:240
http://www.biomedcentral.com/1471-2474/12/240
Page 3 of 9volume between the control group and the two experi-
mental groups treated with 1.5 mg/kg and 7.5 mg/kg
CsA respectively (Table 3).
Compared with the control group, the middle femur
shaft of the experimental group treated with 1.5 mg/kg
or 7.5 mg/kg CsA showed no significant change in the
value of any of the index of the bone biomechanical
proprieties (Table 4).
Compared with the control group, the femoral neck of
rats treated with 7.5 mg/kg CsA showed significantly
lower values of the ultimate force, the ultimate stress and
the Young modulus. However, the femoral neck of rats
treated with 1.5 mg/kg CsA only showed a definite down-
ward trend in all indices of the bone biomechanical pro-
prieties, but the difference did not reach the statistical
significance (Table 5).
Effects of varying doses of CsA on the trabecular bone
architecture
The fourth lumbar vertebra displayed statistically signifi-
cant lower values of the bone volume fraction, the trabe-
cular thickness and the trabecular number between the
control group and the 7.5 mg/kg CsA group. However,
the fourth lumbar vertebra of the rats of the 1.5 mg/kg
CsA group only showed statistically significant lower
values of the bone volume fraction. Compared with the
control group, the fourth lumbar vertebra of both experi-
mental groups showed significantly higher values of the
trabecular separation (Figure 4).
The right proximal tibia metaphysis displayed statisti-
cally significant lower values of the bone volume fraction,
the trabecular thickness and the trabecular number
between the control group and the 7.5 mg/kg CsA group.
However, the right proximal tibia metaphysis of the rats
of the 1.5 mg/kg CsA group only showed statistically sig-
nificant lower values of the bone volume fraction and the
trabecular number. Comparedw i t ht h ec o n t r o lg r o u p ,
the right proximal tibia metaphysis of both experimental
groups showed significantly higher values of the trabecu-
lar separation (Figure 5).
Effects of varying doses of CsA on the cortical thickness
of the femoral shaft
No significant change was observed in the cortical thick-
ness of the middle femoral shaft between the control
group and the two experimental groups (Figure 6).
Discussion
The patients who have undergone organ transplantation
or acquired autoimmune disease always suffer from bone
loss [21-24]. It is thus important to find out whether the
long-term use of CsA will increase these patients’ frac-
ture risk. The present study showed that the CsA therapy
at 7.5 mg/kg significantly reduced the BMD, the ultimate
force and the ultimate stress of the lumbar vertebra and
the proximal femur. The results indicated that the CsA
therapy at 7.5 mg/kg can damage the mechanical proper-
ties and thus may increase the fracture risk of the lumbar
 
Figure 2 Histological examinations of the kidney and liver. Only one rat survived in the 15 mg/kg CsA group. The kidney and liver histology
of the survived rat showed tissue necrosis: (a) Prominent tubular necrosis (black arrow) was found in the renal section; (b) Local necrosis (black
arrow) was detected in the liver section (HE, Original magnification: ×200).
Table 1 Effects of CsA on the liver and kidney function
ALT (U/L) AST (U/L) BUN (mmol/L) Cr (umol/L)
Baseline(n = 8) 47.4 ± 6.2 174.8 ± 34.7 8.0 ± 2.1 79.4 ± 12.3
Control(n = 12) 50.0 ± 6.2 191.3 ± 51.3 8.4 ± 1.8 82.3 ± 10.7
1.5 mg CsA(n = 11) 45.3 ± 8.3 158.6 ± 82.9 9.3 ± 1.5 75.8 ± 15.7
7.5 mg CsA(n = 9) 72.5 ± 26.3 211.2 ± 121.3 11.8 ± 5.0 86.3 ± 17.5
Data are expressed as means ± SD.
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Page 4 of 9vertebra and the proximal femur. Such findings were
consistent with those reported by Epstein et al [25], and
may have important clinical implications.
Osteoporotic fracture is widely recognized as a public
health threat because it is associated with increased risk
of morbidity and mortality, and with significant health
care costs [26,27]. Even in normal population, vertebral
fractures and hip fracture are substantially associated
with the mortality risk. Some recent studies reported
that patients with osteoporotic vertebral fractures have a
significant four-fold increase in mortality compared with
patients without vertebral fractures [28], and that the
mortality after a hip fracture remains significantly
higher, being 11-23% at six months and 22- 29% at one
year from injury [29]. The present results also supported
that if the CsA therapy is applied, the change of BMD of
the vertebra and the hip should be monitored to predict
the fracture risk.
The effects of CsA on the rat skeleton biomechanical
properties closely bear upon both the dose and the
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Figure 3 Effects of CsA on the bone length and the body weight.N os i g n i f i c a n tc h a n g ei nt h eb o n el e n g t ho rt h eb o d yw e i g h tw a s
observed among the control group, the 1.5 mg/kg CsA group and the 7.5 mg/kg CsA group: (a) The bone length of humerus; (b) The bone
length of femur; (c) The bone length of tibia; (d) The body weight. Data are expressed as means (bars) ± SD (error bar).
Table 2 Effect of CsA on the bone mineral density.
BMD (g/cm
2) BMC (g) Area (cm
2)
Lumbar Vertebra
Baseline (n = 8) 0.237 ± 0.018 0.502 ± 0.073 2.124 ± 0.287
Control (n = 12) 0.259 ± 0.026 0.609 ± 0.107 2.343 ± 0.297
1.5 mg CsA (n = 11) 0.204 ± 0.030** 0.473 ± 0.091** 2.325 ± 0.260
7.5 mg CsA (n = 9) 0.201 ± 0.015** 0.462 ± 0.073 ** 2.291 ± 0.462
Proximal Femur
Baseline (n = 8) 0.245 ± 0.038 0.126 ± 0.022 0.513 ± 0.028
Control (n = 12) 0.258 ± 0.046 0.139 ± 0.029 0.536 ± 0.029
1.5 mg CsA (n = 11) 0.181 ± 0.036* 0.099 ± 0.017** 0.542 ± 0.037
7.5 mg CsA (n = 9) 0.171 ± 0.039** 0.092 ± 0.025** 0.530 ± 0.027
Middle Femur
Baseline (n = 8) 0.298 ± 0.075 0.228 ± 0.058 0.762 ± 0.021
Control (n = 12) 0.323 ± 0.068 0.258 ± 0.052 0.794 ± 0.058
1.5 mg CsA (n = 11) 0.311 ± 0.066 0.241 ± 0.058 0.771 ± 0.052
7.5 mg CsA (n = 9) 0.317 ± 0.058 0.243 ± 0.045 0.767 ± 0.065
Data are expressed as means ± SD. Compared with the control group, p < 0.05 *, p < 0.01 **.
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Page 5 of 9duration of administration [10,11]. Goodman et al.
found that the rats receiving 7.5 mg/kg CsA by daily
oral gavages for 84 days showed osteopenia, and the rats
receiving 1.5 mg/kg CsA were relatively bone sparing
[8]. Our results showed that the CsA therapy at either
1.5 mg/kg or 7.5 mg/kg would damage the biomechani-
cal properties of the lumbar vertebra, but neither dose
of CsA therapy had a detrimental effect on the middle
femur, furthermore, CsA therapy at 7.5 mg/kg but not
at 1.5 mg/kg could damage the biomechanical properties
of the proximal femur. Our findings importantly sug-
gested that apart from the doses and duration of CsA
therapy, the effects of CsA on skeletons were also clo-
sely related to the selection of anatomic sites, that is,
the effects of CsA on skeleton are site-specific.
It is well known that the structural and metabolic het-
erogeneity is salient in the bones of rats. The cancellous
bone is mainly located in axial bones with high turn-
over, while the cortical bone is mainly found in long
bones with low turnover. Our results showed that com-
pared with the control group, in the 7.5 mg/kg CsA
therapy group the values of the bone volume fraction,
the trabecular thickness, and the trabecular number of
the lumbar vertebra were significantly reduced, whereas
the value of the middle femur cortical thickness had no
statistically significant change. The variations of these
trabecular bone architectures were consistent with the
changes of the BMD and biomechanical proprieties in
the 7.5 mg/kg CsA therapy group. This is so because
compared with the control group, the values of the
BMD, the ultimate force, the ultimate stress and the
energy absorption per unit of bone volume of the lum-
bar vertebra in this therapy group were significantly
reduced, whereas these values of the middle femur had
no significant change. Our findings suggested that the
lumbar vertebra contained predominantly cancellous
bone and was prone to damage by the CsA, while the
middle femur contained mainly cortical bone and was
resistant to the deterioration of CsA. Our findings are in
accordance with Movsowitz et al.’sr e p o r tt h a tC s Ai n
the dose of 7.5 mg/kg could induce high turnover osteo-
porosis in rats, and the bone loss mainly occurred in
cancellous bone [11]. Our findings are also in agreement
with Klein et al.’s findings that CsA has little effect on
cortical bone in rats [9].
CsA therapy is also associated with renal and hepatic
impairment. In the 15 mg/kg CsA group only one rat
survived. The kidney and liver histology of the survived
r a ts h o w e de x t e n s i v et i s s u en e c r o s i s ,a n dt h es e r u m
ALT, AST, BUN and Cr levels were respectively 2.5, 2.8,
3, and 1.5 times of the averaged levels of the control
group. The eleven rats may have died from the renal
and hepatic impairment. In the 7.5 mg/kg CsA group,
three rats died. Although we could not ascertain the
exact cause for their death, these rats manifested the
same cachexia characteristics before their death as the
rats that died in the 15 mg/kg CsA group. We thus
s p e c u l a t e dt h a tt h e s er a t sm a yh a v ea l s od i e df r o mt h e
renal and hepatic damage. Compared with the control
group, no significant change in body weight and bone
length was observed in either the 1.5 mg/kg or the 7.5
mg/kg CsA therapy group. This may suggest that CsA
Table 3 Effects of CsA on the mechanical parameters of the lumbar vertebra
Baseline
(n = 8)
Control
(n = 12)
1.5 mg CsA
(n = 11)
7.5 mg CsA
(n = 9)
Ultimate force (N) 143.7 ± 24.4 156.9 ± 36.2 119.9 ± 34.7* 113.6 ± 45.8*
Stiffness (N/mm) 688.2 ± 209.7 756.1 ± 258.6 698.7 ± 298.3 547.4 ± 250.1
Energy absorption (mJ) 29.8 ± 14.5 36.4 ± 16.9 24.8 ± 11.7 23.9 ± 13.8
Ultimate stress (GPa) 0.017 ± 0.003 0.017 ± 0.004 0.013 ± 0.003* 0.011 ± 0.005**
Young’s modulus (Gpa) 0.488 ± 0.160 0.444 ± 0.130 0.454 ± 0.213 0.333 ± 0.147
Energy absorption (mJ/mm3) 0.81 ± 0.34 0.77 ± 0.44 0.44 ± 0.24* 0.34 ± 0.28*
Data are expressed as means ± SD. Compared with the control group, p < 0.05 *, p < 0.01 **.
Table 4 Effects of CsA on the mechanical parameters of the middle femurs
Baseline
(n = 8)
Control
(n = 12)
1.5 mg CsA
(n = 11)
7.5 mg CsA
(n = 9)
Ultimate force (N) 112.7 ± 19.1 139.9 ± 23.1 128.6 ± 22.1 131.8 ± 20.3
Stiffness (N/mm) 317.6 ± 87.4 423.6 ± 95.3 347.5 ± 96.4 396.6 ± 89.8
Energy absorption (mJ) 20.1 ± 4.5 23.6 ± 5.4 24.7 ± 5.4 22.9 ± 4.8
Ultimate stress (GPa) 0.098 ± 0.020 0.101 ± 0.016 0.101 ± 0.013 0.096 ± 0.016
Young’s modulus (Gpa) 9.9 ± 2.5 10.9 ± 2.5 9.2 ± 1.5 9.6 ± 2.3
Energy absorption (mJ/mm3) 0.49 ± 0.08 0.46 ± 0.07 0.53 ± 0.14 0.47 ± 0.08
Data are expressed as means ± SD.
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effect on the rat body and bone growth.
The exact mechanism that leads to the deterioration
of skeletal biomechanical properties after CsA therapy
remains inconclusive. In-vivo studies have demonstrated
that the parameters of osteoblast and osteoclast function
are both increased [10,30], and our results have shown
that CsA therapy at 1.5 and 7.5 mg/kg has no inhibitory
effect on rat bone growth. Thus, it is unlikely that CsA
has had a direct toxic effect on bone cells. In all likeli-
hood, it maybe a combination of the two possibilities: 1)
CsA may act directly on bone cells and affect their abil-
ity to secrete local autocrine factors or respond to sys-
temic hormones. 2) CsA may have an indirect action on
bone via their effects on the immune system [30,31].
Considering that the kidney is closely related to the
bone mineral metabolism [32], we speculated that CsA
therapy, especially in high dose, may have an indirect
action on bone through a mechanism of abnormal
mineral homeostasis due to impaired kidney function.
It has been reported that bone growth in rats slows
drastically at 3 months of age and plateaus by 12
months [33], and that 3-month-old rats are more sensi-
tive to the CsA therapy, apart from being in much bet-
ter health condition and thus able to endure long-term
CsA therapy [34,35]. In light of the previous reports, we
used 3-month-old rat as the animal model in our pre-
sent study. This animal model shares many characteris-
tics with its human analog of post-transplantation
osteoporosis, including a similar pattern of bone loss
and a positive response to bisphosphonates therapy that
is beneficial to humans [7]. However, the characteristics
of bone remodeling in cortical bone in rats are not con-
gruent to the human case [33]. The lack of intracortical
bone remodeling in cortical bone may contribute to the
resistance of the femur diaphysis to the damage of CsA
Table 5 Effects of CsA on the mechanical parameters of the femoral neck
Baseline
(n = 8)
Control
(n = 12)
1.5 mg CsA
(n = 11)
7.5 mg CsA
(n = 9)
Ultimate force (N) 59.3 ± 11.1 70.4 ± 7.2 62.9 ± 13.2 54.9 ± 14.8*
Stiffness (N/mm) 108.4 ± 23.1 115.0 ± 21.3 103.3 ± 20.2 105.6 ± 26.8
Energy absorption (mJ) 31.0 ± 10.4 30.3 ± 7.0 28.8 ± 11.1 27.9 ± 15.5
Ultimate stress (GPa) 0.178 ± 0.016 0.196 ± 0.010 0.175 ± 0.033 0.135 ± 0.026**
Young’s modulus (Gpa) 2.25 ± 0.47 2.37 ± 0.39 2.08 ± 0.54 1.67 ± 0.55**
Data are expressed as means ± SD. Compared with the control group, p < 0.05 *, p < 0.01 **.
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Figure 4 Effects of CsA on the lumbar vertebral trabecular bone architecture. Compared with the control group: (a) The values of the
bone volume fraction were significantly decreased in the 1.5 mg/kg and the 7.5 mg/kg CsA group; (b) The values of the trabecular thickness
were significantly decreased in the 7.5 mg/kg CsA group; (c) The values of the trabecular number were significantly decreased in the 7.5 mg/kg
CsA group; (d) The values of the trabecular separation were significantly increased in the 1.5 mg/kg and the 7.5 mg/kg CsA group. Data are
expressed as means (bars) ± SD (error bar). Compared with the control group: p < 0.05 *, p < 0.01 **.
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Page 7 of 9therapy. Therefore this model should not be used to
assess the response of cortical bone to the CsA therapy.
Conclusions
Long-term use of CsA can weaken the biomechanical
properties and thus increase the fracture rate of the
lumbar vertebra and the proximal femur. However, CsA
therapy has less effect on the middle femur shaft. The
effects of CsA on skeleton are site-specific.
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